サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1678737

ギラン・バレー症候群診断の市場規模、シェア、動向レポート：検査別、最終用途別、地域別、セグメント予測、2025年～2030年

Guillain-Barre Syndrome Diagnostics Market Size, Share & Trends Report By Test (Lumbar Puncture, Electromyography), By End-use (Hospitals And Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ギラン・バレー症候群診断の市場規模、シェア、動向レポート：検査別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年02月14日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ギラン・バレー症候群診断薬市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のギラン・バレー症候群診断市場規模は、2025～2030年にかけてCAGR 2.8％を記録し、2030年には1億6,990万米ドルに達する見込みです。

特に感染症の多い地域でのギラン・バレー症候群の発生率の増加が大きく寄与しています。呼吸器疾患や胃腸疾患などの感染症がGBSに先行することが多く、効果的な診断ツールに対する需要が高まっています。例えば、ミネソタ大学が2023年10月に発表した研究では、GBS症例の67％がこうした感染症に先行しており、タイムリーな診断の必要性が強調されています。

診断技術の進歩も市場拡大に重要な役割を果たしています。筋電図検査（EMG）と神経伝導検査における技術革新は、GBS診断の精度とスピードを向上させました。このような技術的改善により、医療専門家は本症を早期に発見できるようになり、迅速な介入と患者の転帰改善が促進されます。臨床現場における先進的診断ツールの統合は、患者ケアの向上へのコミットメントを反映して、ますます普及してきています。

医療従事者や一般住民の間でGBSに対する認識が高まっていることが、診断薬市場をさらに押し上げています。教育的な取り組みや情報発信の増加は、症状の早期発見とその後の診断検査につながっています。このような意識の高まりにより、患者はタイムリーで適切な治療を受けられるようになり、診断の遅れに伴う重篤な合併症のリスクが軽減されています。その結果、診断サービスへの需要が高まり、市場の成長に寄与しています。

高齢者の拡大は、GBS診断薬市場に影響を与えています。高齢者はGBSの引き金となる感染症にかかりやすいため、効果的な診断対策が必要となります。世界保健機関（WHO）の2021年予測によると、2030年までに世界の6人に1人が60歳以上になり、その数は2020年の10億人から2050年には21億人に増加すると予想されています。この人口動態の変化は、高齢者におけるGBS症例の増加が予想されるため、アクセスしやすく正確な診断ツールの重要性を強調しています。

同市場の主要企業は、地理的拡大、提携、パートナーシップ、合弁事業などの戦略的イニシアチブを実施し、市場での存在感を高めています。

ギラン・バレー症候群診断市場レポートハイライト

  • 市場の検査セグメントには、腰椎穿刺、筋電図、神経伝導検査、その他が含まれます。腰椎穿刺部門は2024年に市場をリードし、45.1%の最大収益シェアを占め、GBS診断の確認に不可欠な役割を果たすことから、予測期間中に最も速い複合年間成長率（CAGR）3.0%が見込まれます。
  • 最終用途部門は、病院クリニックと診断ラボで構成されます。2024年には、病院クリニックが63.0％の売上シェアを獲得して市場をリードし、先進的診断ツールの統合と患者管理プロトコルの改善を通じて大きな成長を牽引しました。
  • アジア太平洋は2024年に41.8%の収益シェアを獲得し、世界市場を独占しました。認知度の向上、医療インフラの改善、診断率の上昇などの要因が市場拡大を促進しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ギラン・バレー症候群診断市場の変数、動向、範囲

  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
  • ギラン・バレー症候群診断市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析
    • 使用事例

第4章 ギラン・バレー症候群診断市場：検査別、推定・動向分析

  • 検査市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 検査別ギラン・バレー症候群診断市場の世界的展望
  • 腰椎穿刺
  • 神経伝導検査
  • 筋電図検査
  • その他

第5章 ギラン・バレー症候群診断市場： 最終用途別、推定・動向分析

  • 最終用途市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 最終用途別ギラン・バレー症候群診断市場の世界的展望
  • 病院とクリニック
  • 診断ラボ
  • その他

第6章 ギラン・バレー症候群診断市場：地域推定・動向分析、製品別、検査別、最終用途別

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 世界地域市場スナップショット
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • 主要企業の市場シェア/ポジション分析、2024年
  • 企業プロファイル
    • Cadwell Industries, Inc
    • Natus Medical Incorporated
    • Nihon Kohden Corporation
    • Medtronic plc
    • Bionen Medical Devices
    • Deymed Diagnostic
    • Neurosoft
    • Alpine Biomed
    • EMS Biomedical
    • Rochester Electro-Medical, Inc
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 4 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 6 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 8 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 10 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 12 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 13 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 14 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 16 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 17 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 18 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 20 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 22 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 24 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 25 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 26 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 28 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 32 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 33 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 34 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 36 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 38 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 40 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 42 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 44 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 46 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 48 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 50 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 52 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 56 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Guillain-Barre Syndrome (GBS) Diagnostics market outlook
  • Fig. 9 Guillain-Barre Syndrome (GBS) Diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Guillain-Barre Syndrome (GBS) Diagnostics market driver impact
  • Fig. 15 Guillain-Barre Syndrome (GBS) Diagnostics market restraint impact
  • Fig. 16 Guillain-Barre Syndrome (GBS) Diagnostics market strategic initiatives analysis
  • Fig. 17 Guillain-Barre Syndrome (GBS) Diagnostics market: Test analysis
  • Fig. 18 Guillain-Barre Syndrome (GBS) Diagnostics market: Test outlook and key takeaways
  • Fig. 19 Clinical writing market estimates and forecast, 2018 - 2030
  • Fig. 20 Lumbar puncture market estimates and forecast, 2018 - 2030
  • Fig. 21 Nerve conduction studies market estimates and forecast, 2018 - 2030
  • Fig. 22 Electromyography market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Guillain-Barre Syndrome (GBS) Diagnostics market: End use movement analysis
  • Fig. 25 Guillain-Barre Syndrome (GBS) Diagnostics market: End use outlook and key takeaways
  • Fig. 26 Hospitals and clinics market estimates and forecast, 2018 - 2030
  • Fig. 27 Diagnostic laboratories market estimates and forecast, 2018 - 2030
  • Fig. 28 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional movement analysis
  • Fig. 29 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional outlook and key takeaways
  • Fig. 30 Global Guillain-Barre Syndrome (GBS) Diagnostics market share and leading players
  • Fig. 31 North America market share and leading players
  • Fig. 32 Europe market share and leading players
  • Fig. 33 Asia Pacific market share and leading players
  • Fig. 34 Latin America market share and leading players
  • Fig. 35 Middle East & Africa market share and leading players
  • Fig. 36 North America: SWOT
  • Fig. 37 Europe SWOT
  • Fig. 38 Asia Pacific SWOT
  • Fig. 39 Latin America SWOT
  • Fig. 40 MEA SWOT
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030
  • Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 48 France market estimates and forecasts, 2018 - 2030
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 52 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 53 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 54 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 55 China market estimates and forecasts, 2018 - 2030
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 57 India market estimates and forecasts, 2018 - 2030
  • Fig. 58 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 60 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 61 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 62 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 63 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 64 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 66 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 67 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 68 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 69 Market share of key market players- Guillain-Barre Syndrome (GBS) Diagnostics market
  • Fig. 70 Key Company Categorization
  • Fig. 71 Company Market Share/Position Analysis, 2024
  • Fig. 72 Strategic Framework
目次
Product Code: GVR-4-68040-522-7

Guillain-Barre Syndrome Diagnostics Market Growth & Trends:

The global guillain-barre syndrome diagnostics market size is expected to reach USD 169.9 million by 2030, registering a CAGR of 2.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. driven by several key factors. A significant contributor is the increasing incidence of Guillain-Barre syndrome (GBS), particularly in regions with high rates of infectious diseases. Infections such as respiratory or gastrointestinal illnesses often precede GBS, leading to a heightened demand for effective diagnostic tools. For instance, a study from the University of Minnesota in October 2023 highlighted that 67% of GBS cases were preceded by such infections, underscoring the need for timely diagnosis.

Advancements in diagnostic techniques have also played a crucial role in market expansion. Innovations in electromyography (EMG) and nerve conduction studies have enhanced the accuracy and speed of GBS diagnosis. These technological improvements enable healthcare professionals to detect the syndrome earlier, facilitating prompt intervention and better patient outcomes. The integration of advanced diagnostic tools in clinical settings has become increasingly prevalent, reflecting a commitment to improving patient care.

The growing awareness of GBS among healthcare providers and the general population has further propelled the diagnostics market. Educational initiatives and increased information dissemination have led to earlier recognition of symptoms and subsequent diagnostic testing. This heightened awareness ensures that patients receive timely and appropriate care, reducing the risk of severe complications associated with delayed diagnosis. Consequently, the demand for diagnostic services has risen, contributing to market growth.

The expanding geriatric population has influenced the market for GBS diagnostics. Older individuals are more susceptible to infections that can trigger GBS, necessitating effective diagnostic measures. According to the World Health Organization's 2021 forecast, by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. This demographic shift underscores the importance of accessible and accurate diagnostic tools to manage the anticipated increase in GBS cases among the elderly.

Key players in the market are implementing strategic initiatives such as geographical expansion, collaborations, partnerships, and joint ventures to strengthen their market presence.

Guillain-Barre Syndrome Diagnostics Market Report Highlights:

  • The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest compound annual growth rate (CAGR) of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis.
  • The end-use segment comprises hospitals & clinics, and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols.
  • Asia Pacific dominated the global market with a revenue share of 41.8% in 2024. Factors such as rising awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Guillain-Barre Syndrome (GBS) Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Guillain-Barre Syndrome (GBS) Diagnostics Market: Test Estimates & Trend Analysis

  • 4.1. Test Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by Product Test Outlook
  • 4.4. Lumbar Puncture
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Nerve Conduction Studies
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Electromyography
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by End Use Outlook
  • 5.4. Hospitals and Clinics
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Guillain-Barre Syndrome (GBS) Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Test, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Cadwell Industries, Inc
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology test benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Natus Medical Incorporated
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology test benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Nihon Kohden Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology test benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Medtronic plc
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology test benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Bionen Medical Devices
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology test benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Deymed Diagnostic
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology test benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Neurosoft
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology test benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Alpine Biomed
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology test benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. EMS Biomedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology test benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Rochester Electro-Medical, Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology test benchmarking
      • 7.4.10.4. Strategic initiatives